Metronomic chemotherapy and radiotherapy as salvage treatment in refractory or relapsed pediatric solid tumours

Original Article

Metronomic chemotherapy and radiotherapy as salvage treatment in refractory or relapsed pediatric solid tumours

A.M. Ali, MD*, M.I. El-Sayed, MD




Metronomic chemotherapy (mctx) combined with radiation therapy (rt) is an emerging anticancer strategy. The aim of the present study was to assess the efficacy of mctx combined with rt as salvage treatment in children with refractory or relapsed solid malignancies.


This prospective study enrolled patients with refractory or relapsed pediatric solid tumours from January 2013 to January 2015. Treatment consisted of 3–12 courses of mctx in all patients, followed by rt in patients who experienced local recurrence, distant metastases, or both. Each course of mctx consisted of oral celecoxib 100–400 mg twice daily (days 1–42), intravenous vinblastine 3 mg/m2 weekly (weeks 1–6), oral cyclophosphamide 2.5 mg/m2 daily (days 1–21), and oral methotrexate 15 mg/m2 twice weekly (days 21–42). Statistical methods used were the log-rank test and binary logistic regression.


A favourable disease response (partial response or stable disease) was seen in 49 of 64 patients (76.6%), with mild acute toxicity occurring in 41 (64%). After a median follow-up of 14 months, 1-year overall survival was 62%. Pattern of disease relapse (p < 0.0001), time from initial treatment to relapse (p = 0.0002), and response to treatment (p < 0.0001) significantly affected survival. Age was the only factor that significantly correlated with treatment toxicity (p = 0.002; hazard ratio: 3.37; 95% confidence interval: 1.53 to 7.35)


Combining mctx with rt resulted in a favourable response rate, minimal toxicity, and 62% 1-year overall survival in patients with heavily pretreated recurrent disease. Patients with localized late recurrence or disease progression are the most likely to benefit from this regimen.

KEYWORDS: Antiangiogenic therapy, palliative irradiation, treatment outcomes


Effectively treating recurrent pediatric solid malignancies is not an easy task. Most of these patients have a dismal prognosis and die within 2 years1. Conventional chemotherapy given at maximal tolerated doses results in disease control in pediatric cancer patients, but is frequently accompanied by side effects. Furthermore, treatment options for patients with disease progression after chemotherapy remain limited2. Chemotherapy regimens inhibit tumour angiogenesis, thus suppressing tumour vascularization3,4; however, long intervals between chemotherapy courses result in regrowth of the endothelial cells and further angiogenesis5. The antiangiogenic effects can be enhanced by shortening the period between chemotherapy cycles (continuous low-dose chemotherapy)6, which also increases the proapoptotic effects of some chemotherapeutic drugs in tumour cells7,8.

Low-dose chemotherapy administered continuously is called metronomic chemotherapy (mctx), and it is an option for the treatment of most cancer patients with disease progression8. Various chemotherapeutic drugs such as cyclophosphamide, methotrexate, and vinblastine that are cytotoxic to endothelial cells but not to non-endothelial cells are the mainstays of mctx6,9.

Low-dose cyclophosphamide has been documented to have a potential role in reducing the number and suppressing the function of regulatory T cells10, resulting in tumour suppression and enhanced response11. In addition, low, non-cytotoxic concentrations of methotrexate and vinblastine promote maturation of dendritic cells and their antigen-presenting activity, and therefore support the development of antitumour immunity in tumour-bearing hosts12. Treatment of cells in culture with cox-2 inhibitor (celecoxib) is likely to lead to cell-cycle arrest13 because of downregulation of the cyclin-dependent kinases that drive cell through the cell cycle8. That finding suggests that the cytotoxic effects of some chemotherapeutic agents might be potentiated when cox-2 inhibitors are added11. For the present study, we therefore chose a 4-agent mctx regimen—celecoxib, cyclophosphamide, methotrexate, and vinblastine—with varying mechanisms of action (antiangiogenic, immunostimulatory, and apoptotic)8, and we evaluated the efficacy of mctx using that regimen followed by rt for treatment of patients with refractory or relapsed pediatric solid tumours who had been treated with standard initial chemotherapy at diagnosis and salvage treatment at time of disease relapse.


Study Population

This prospective study was conducted at the pediatric oncology and radiotherapy departments of the South Egypt Cancer Institute, Assiut University, from January 2013 to January 2015, after registration of the study in the scientific research unit and approval by the institutional review board and ethics committee. The study enrolled pediatric patients 18 years of age or younger with relapsed or progressive solid tumours and adequate organ function, particularly defined as serum creatinine less than 1.5 mg/dL, total bilirubin 1.5 mg/dL or less, transaminases no more than twice the normal limit, hemoglobin 9.0 g/dL or greater, platelets 100,000/mm3 or greater, white cell count 2000/mm3 or greater, and absolute neutrophil count 1000/mm3 or greater. Informed written consent was obtained from the parents of all patient before study enrolment. Patients with solid tumours that had recurred despite 2 or more regimens of therapy (given at initial diagnosis and for first relapse), were treated by mctx, followed in most patients by rt to local and distant metastatic sites.


Treatment consisted of 3 cycles of mctx, each of 6 weeks’ duration, followed by 1 week of rest. The chemotherapy consisted of celecoxib, cyclophosphamide, vinblastine, and methotrexate (Table i). A treatment duration of at least 21 weeks (3 cycles) was planned. Treatment beyond 21 weeks was continued in patients with either stable disease or a partial response.

TABLE I Drug and dosing schedule for metronomic chemotherapy


Tumour size was evaluated using the method appropriate to the tumour site and size. The bi-dimensional measurements were made using ultrasonography or computed tomography imaging at study entry, after each mctx cycle, and at study termination. Disease status was evaluated using World Health Organization response criteria:

  • ■ Progressive disease (pd): 25% increase in tumour size, or appearance of new lesions

  • ■ Stable disease (sd): neither partial response nor progression

  • ■ Partial response (pr): at least 50% decrease in tumour size

  • ■ Complete response: disappearance of all known lesions

Drug toxicity was evaluated using World Health Organization toxicity criteria14. Treatment was terminated by physician decision in the presence of disease progression or unacceptable toxicity.

RT Techniques

Patients who entered the study with isolated local relapse received mctx followed by local rt (if not previously irradiated); those who entered with distant metastasis received mctx followed by rt to the distant metastatic sites.

Patients with isolated local relapse were planned using 3-dimensional computed tomography for delineation of the gross target volume and critical structures, with the patient in supine position. Prone position was used in patients with back lesions. The clinical target volume included a 0.5-cm margin around the site of recurrent disease evident after the mctx salvage treatment. The planning target volume included a 0.5-cm margin around clinical target volume. Conformal rt using 6 MV photon beams and customized blocks was given. The total radiation dose was assigned according to tumour type and site, prescribed to the isocentre. A total dose reduced by 13%, with a hypofractionated schedule (3 fractions per week), was given to younger patients who were anesthetized for immobilization during the radiation session. The clinical target volume had to be covered by the 95% isodose line. Patients with distant relapse received palliative rt at a dose of 30 Gy in 10 fractions.

Table ii summarizes the treatments given by histopathologic tumour type.

TABLE II Summary of treatment by pathologic type


Follow-Up Visits

At the end of treatment, patients were followed monthly during the study period by physical examination, routine laboratory investigations, and radiologic studies to assess response to treatment.

Statistical Methods

The study cut-off point was 1 January 2015. Overall survival (os) was defined as the interval from enrolment (date of disease relapse or progression) to the date of death from any cause or to last follow-up. Univariate analysis by the log-rank test was used to examine differences in os rates. Binary logistic regression was used to assess correlations between toxicity and various prognostic factors.


Patient Characteristics

The study cohort included 64 patients [36 boys (56%), 28 girls (44%)] with a median age of 7 years (range: 3–17 years), of whom 20 (31%) were 5 years of age or younger, 25 (39%) were 6–11 years of age, and 19 (30%) 12–18 years of age. The most common diagnoses in the group were rhabdomyosarcoma (n = 14, 22%), neuroblastoma (n = 13, 20%), Wilms tumour (n = 10, 16%), brain tumour and peripheral primitive neuroectodermal tumour (n = 9 each, 14%). Most patients presented with disease relapse (n = 51, 80%); the remaining 13 presented with progressive disease (20%). In 16 patients, the relapse was local only; 35 patients presented with metastatic disease.

Of the 64 patients, 41 (64%) received rt—15 to local sites, and 26 to distant metastatic sites (Table ii). The interval between initial treatment at diagnosis and enrolment of patients onto mctx and rt ranged between 5 months and 36 months (median: 16 months). Early relapse (<18 months) or disease progression occurred in 39 patients (61%), and late relapse (≥18 months) occurred in 25 patients (39%).

Treatment Outcomes

After mctx and rt, most patients (n = 49, 77%) experienced a favourable disease response; 22 (34%) experienced a pr, and 27 (42%) experienced sd. On the other hand, pd developed in 15 patients (23%). Acute toxicities (Table iii) were mild: grade 1 hematologic toxicities (n = 26, 41%), nonhematologic toxicities (n = 10, 16%), or a combination (n = 5, 8%). In 23 patients (36%), no toxicities were observed.

TABLE III Treatment outcomes for patients with refractory or relapsed pediatric solid tumours 3–6 Courses of VIP chemotherapy


Anemia was the most common hematologic toxicity (n = 16), and peripheral neuropathy was the most common nonhematologic toxicity (n = 6). Binary logistic regression showed that age was the only factor that correlated significantly with toxicity [p = 0.002; hazard ratio (hr): 3.37; 95% confidence interval (ci): 1.53 to 7.35]. An analysis of toxicity by age group (Table iv) showed that grade 1 treatment- related toxicity occurred more often in the group 12–18 years of age (17 of 19 patients, 89%) than in the group 5 years of age and younger (8 of 20 patients, 40%). The correlation between response to treatment and treatment-related toxicity (Pearson correlation) was not statistically significant (p = 0.124).

TABLE IV Presence or absence of toxicity by patient age group


Survival Analysis

After a median follow-up of 14 months (range: 3–23 months), the 1-year os rate was 62.3% (Figure 1). Univariate analysis showed 1-year os rates of 20.5%, 83.2%, 64.2%, and 68.8% for patients with pd, isolated local recurrence, isolated metastatic disease, and combined disease relapse respectively (p = 0.0003). The 1-year os was higher for patients who experienced a pr (82%) than for patients who experienced sd (70%) or pd (17%, p < 0.0001), and higher for those experiencing late relapse (84%) than for those experiencing early relapse or pd (48%, p = 0.0002). On the other hand, the 1-year os rates were not significantly different by age group (p = 0.37), sex (p = 0.17; hr: 1.7; 95% ci: 0.799 to 3.65), pathologic type (p = 0.12), or treatment-related toxicity (p = 0.056; hr: 0.48; 95% ci: 0.23 to 1.02; Table v, Figures 25).



FIGURE 1 Overall survival in the patient cohort.

TABLE V Univariate analysis of factors that might affect overall survival (OS)




FIGURE 2 Overall patient survival by pattern of disease relapse. LR = local relapse; MD = metastatic disease; Combined = both relapse types; PD = progressive disease.



FIGURE 3 Overall patient survival by response to treatment. PR = partial response; SD = stable disease; PD = progressive disease.



FIGURE 4 Overall patient survival by treatment-related toxicity.



FIGURE 5 Overall patient survival by relapse (early or late) after treatment received at initial diagnosis.


In the present study, we used a mctx regimen consisting of 3 oral drugs (celecoxib, cyclophosphamide, methotrexate) and 1 intravenous drug (vinblastine) in conjunction with rt. The inclusion of celecoxib in the mctx regimen was justified by reports from clinical trials suggesting some activity in pediatric malignancies when mctx is used in conjunction with cox-2 inhibitors1520. Vinorelbine21 and etoposide16 have been recommended for use in mctx regimens based on their efficacy in pediatric patients with previously treated solid tumours. Because those two drugs were not available at our institute, we chose to use methotrexate and vinblastine, which have been included in other mctx studies8,18. The celecoxib–vinblastine–cyclophosphamide–methotrexate drug regimen used in the present study is likely to have various mechanisms of antiangiogenesis without overlapping toxicities, resulting in inhibition of various steps in the tumour neovascularization process12,18.

A response, defined as pr or sd after 6 months, was achieved in 77% of the study patients (34% pr, 42% sd). The higher rate of sd compared with pr in the present study can possibly be explained on the grounds that, in recurrent tumours, antiangiogenic agents inhibit neovascularization (resulting in sd) rather than established vasculature (which would result in shrinkage and pr). However, for most cancer patients who have already been treated in the first and second chemotherapy lines, and for whom no other efficient salvage therapy is anticipated, stopping tumour growth can be considered a favourable outcome16.

Univariate analysis showed favourable 1-year os rates for patients with isolated local recurrence and with late relapse. The encouraging response rate and the relatively favourable os rate (1-year os: 62%) in our cohort might be explained by preclinical and clinical findings of a direct relationship between rt and tumour vasculature. The blood vessels in tumours are dilated and tortuous, leading to non-uniform distribution of chemotherapeutic drugs and oxygen22,23. Antiangiogenic treatment normalizes tumour vasculature and oxygenation24. A combination of rt and mctx can lead to better clinical efficacy in various cancers, because antiangiogenic therapy increases oxygenation and radiosensitivity23,25, augmenting radiation efficacy26. Our findings might confirm a study reported by Sterba et al.15, who showed encouraging results for rt combined with metronomic temozolomide in children with medulloblastoma.

The drug regimen used in the current study was well tolerated in our pretreated patients; it produced only mild acute toxicities and did not result in treatment interruption. No patient required blood transfusion or growth factor administration. More than one third of the patients (n = 23, 36%) showed no toxicities. The use of low intravenous doses of vinblastine, with oral administration of the other 3 drugs in the regimen at home, was convenient for the prolonged and frequent dosing. Those findings are confirmed by other studies1618 reporting that chronic administration of low-dose chemotherapy results in less toxicity and better quality of life in patients with advanced or relapsed cancer.

Binary logistic regression showed that age was significantly correlated with treatment toxicity (p = 0.002; hr: 3.37; 95% ci: 1.53 to 7.35), with grade 1 toxicity being present in 89% (17 of 19) of patients 12–18 years of age and in 40% (8 of 20) of patients 5 years of age or younger. That result might be explained by the fact that cells of normal tissues in younger children are dividing and multiplying more rapidly than they are in older children, resulting in faster recovery from mctx-related toxicities. That hypothesis accords with a report from Rask et al.27, who found that increasing age was a significant risk factor for chemotherapy-related toxicity.


In children with relapsed pediatric solid tumours, especially those with isolated local relapse and late relapse, mctx combined with rt resulted in a favourable response rate with minimal toxicity. The 1-year os rate was 62%. Although the principal target of mctx is tumour neovasculature, an mctx regimen can directly attack tumour-cell proliferation earlier in the disease process. Future studies are recommended to evaluate the efficacy of mctx as first salvage treatment in patients with relapsed pediatric solid tumours, especially those with localized disease and late relapse.


We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare that we have none.

Author Affiliations

*Department of Pediatric Oncology, South Egypt Cancer Institute, Assiut University, Egypt.
Department of Radiotherapy, South Egypt Cancer Institute, Assiut University, Egypt.


1. Zwerdling T, Krailo M, Monteleone P, et al. Phase ii investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children’s Oncology Group. Cancer 2006;106:1821–8.
cross-ref  pubmed  

2. Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010;7:455–65.
cross-ref  pubmed  

3. Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: hemotherapeutics as antiangiogenics. J Clin Oncol 2001;19:1195–206.

4. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000;60:1388–93.

5. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423–36.
cross-ref  pubmed  

6. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878–86.

7. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and vegf receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15–24.
cross-ref  pubmed  pmc  

8. Bahl A, Bakhshi S. Metronomic chemotherapy in progressive pediatric malignancies: old drugs in new package. Indian J Pediatr 2012;79:1617–22.
cross-ref  pubmed  

9. André N, Abed S, Orbach D, et al. Pilot study of a pediatric metronomic 4-drug regimen. Oncotarget 2011;2:960–5.
cross-ref  pubmed  pmc  

10. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4+ 25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105:2862–8.

11. Gupta RA, Dubois RN. Combinations for cancer prevention. Nat Med 2000;6:974–5.
cross-ref  pubmed  

12. Kaneno R, Shurin GV, Turkova IL, Shurin MR. Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J Transl Med 2009;7:58.
cross-ref  pubmed  pmc  

13. Hsueh CT, Chiu CF, Kelsen DP, Schwartz GK. Selective inhibition of cyclooxygenase-2 enhances mitomycin-C–induced apoptosis. Cancer Chemother Pharmacol 2000;45:389–96.

14. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: who Offset Publication; 1979.

15. Sterba J, Pavelka Z, Slampa P. Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors. Neoplasma 2002;49:117–20.

16. Kieran MW, Turner CD, Rubin JB, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 2005;27:573–81.
cross-ref  pubmed  

17. Fousseyni T, Diawana M, Pasquier E, André N.: Children treated with metronomic chemotherapy in a low-income country: metro-mali-01. J Pediatr Hematol Oncol 2011;33:31–4.

18. Stempak D, Gammon J, Halton J, Moghrabi A, Koren G, Baruchel SA. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol 2006;28:720–8.
cross-ref  pubmed  

19. Choi LM, Rood B, Kamani N, et al. Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors. Pediatr Blood Cancer 2008;50:970–5.

20. Minturn JE, Janss AJ, Fisher PG, et al. A phase ii study of metronomic oral topotecan for recurrent childhood brain tumors. Pediatr Blood Cancer 2011;56:39–44.

21. Casanova M, Ferrari A, Bisogno G, et al. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer 2004;101:1664–71.
cross-ref  pubmed  

22. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249–57.
cross-ref  pubmed  

23. Kobayashi H, Lin PC. Antiangiogenic and radiotherapy for cancer treatment. Histol Histopathol 2006;21:1125–34.

24. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987–9.
cross-ref  pubmed  

25. Ciric E, Sersa G. Radiotherapy in combination with vascular-targeted therapies. Radiol Oncol 2010;44:66–78.

26. Kleibeuker EA, Griffioen AW, Verheul HM, Slotman BJ, Thijssen VL. Combining angiogenesis inhibition and radiotherapy: a double-edged sword. Drug Resist Updat 2012;15:173–82.
cross-ref  pubmed  

27. Rask C, Albertioni F, Bentzen SM, Schroeder H, Peterson C. Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia—a logistic regression analysis. Acta Oncol 1998;37:277–84.

Correspondence to: Mohamed Ibrahim El-Sayed, Department of Radiotherapy and Nuclear Medicine, South Egypt Cancer Institute, Assiut University, Al-methak Street, Assiut, Egypt. E-mail:

(Return to Top)

Current Oncology, VOLUME 23, NUMBER 3, June 2016

Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)